Covid 19 Research using Clinical Trials (Home Page)
Report for D011236: Prediabetic State NIH
(Synonyms: Predi, Predia, Prediabet, Prediabeti, Prediabetic State)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (4)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1626 | Low-Carbohydrate Diet Wiki | 0.71 |
| drug579 | CPI-006 Wiki | 0.71 |
| drug1739 | Metformin XR Wiki | 0.71 |
| drug2122 | Placebo Wiki | 0.04 |
Correlated MeSH Terms (7)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D006943 | Hyperglycemia NIH | 0.71 |
| D018149 | Glucose Intolerance NIH | 0.71 |
| D050197 | Atherosclerosis NIH | 0.50 |
| D004700 | Endocrine System Diseases NIH | 0.50 |
| D008659 | Metabolic Diseases NIH | 0.41 |
| D044882 | Glucose Metabolism Disorders NIH | 0.41 |
| D003920 | Diabetes Mellitus, NIH | 0.17 |
Correlated HPO Terms (4)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0011998 | Postprandial hyperglycemia HPO | 0.71 |
| HP:0000818 | Abnormality of the endocrine system HPO | 0.50 |
| HP:0002621 | Atherosclerosis HPO | 0.50 |
| HP:0000819 | Diabetes mellitus HPO | 0.17 |
There are 2 clinical trials
Clinical Trials
1 CSP #2002 - Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes (VA-IMPACT)
This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in patients who have pre-diabetes and heart or blood vessel problems.
NCT02915198 Prediabetic State Atherosclerosis Metformin Drug: Metformin XR Drug: Placebo MeSH:Atherosclerosis Prediabetic State
HPO:Atherosclerosis Type IV atherosclerotic lesion
Primary Outcomes
Description: The primary outcome measure is the time to first occurrence of death, non-fatal myocardial infarction or stroke, hospitalization for unstable angina with objective evidence of acute myocardial ischemia, or coronary revascularization driven by acute or progressive symptoms.
Measure: Time in days to death, non-fatal myocardial infarction, stroke, hospitalization for unstable angina, or symptom-driven coronary revascularization Time: through study completion, an average of 4.5 years
Secondary Outcomes
Description: Time to first occurrence of death, myocardial infarction, or stroke
Time to first occurrence of a primary endpoint event, peripheral arterial disease event, or hospitalization for congestive heart failure
Cumulative incidence of all components of the primary endpoint, including recurrent or multiple events in the same participant
Cumulative incidence and time to first occurrence of each component of the primary outcome measure, peripheral arterial disease events, and hospitalization for congestive heart failure
Measure: Time in days to Cardiovascular Outcomes Time: through study completion, an average of 4.5 years
Description: Time to new or recurrent diagnosis of a malignancy or death from a malignancy
Measure: Time in days to Oncologic Outcome Time: through study completion, an average of 4.5 years
Description: Time to new diagnosis of type 2 diabetes (ADA criteria)
Measure: Time in days to Diabetes Outcome Time: through study completion, an average of 4.5 years
2 Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial
Primary Outcomes
Description: The primary outcome measure is the time to first occurrence of death, non-fatal myocardial infarction or stroke, hospitalization for unstable angina with objective evidence of acute myocardial ischemia, or coronary revascularization driven by acute or progressive symptoms.
Measure: Time in days to death, non-fatal myocardial infarction, stroke, hospitalization for unstable angina, or symptom-driven coronary revascularization Time: through study completion, an average of 4.5 yearsSecondary Outcomes
Description: Time to first occurrence of death, myocardial infarction, or stroke Time to first occurrence of a primary endpoint event, peripheral arterial disease event, or hospitalization for congestive heart failure Cumulative incidence of all components of the primary endpoint, including recurrent or multiple events in the same participant Cumulative incidence and time to first occurrence of each component of the primary outcome measure, peripheral arterial disease events, and hospitalization for congestive heart failure
Measure: Time in days to Cardiovascular Outcomes Time: through study completion, an average of 4.5 yearsDescription: Time to new or recurrent diagnosis of a malignancy or death from a malignancy
Measure: Time in days to Oncologic Outcome Time: through study completion, an average of 4.5 yearsDescription: Time to new diagnosis of type 2 diabetes (ADA criteria)
Measure: Time in days to Diabetes Outcome Time: through study completion, an average of 4.5 yearsThe proposed randomized controlled trial will test the effect of a low-carbohydrate diet on hemoglobin A1c among individuals with elevated hemoglobin A1c that are within the range of prediabetes or diabetes. Results may provide evidence about the role of carbohydrate restriction in individuals with or at high risk of type 2 diabetes.
NCT03675360 Diabetes PreDiabetes Metabolic Disease Hyperglycemia Diet Modification Glucose Intolerance Glucose Metabolism Disorders (Including Diabetes Mellitus) Endocrine System Diseases Behavioral: Low-Carbohydrate Diet MeSH:Diabetes Mellitus Hyperglycemia Prediabetic State Glucose Intolerance Metabolic Diseases Glucose Metabolism Disorders Endocrine System Diseases
HPO:Abnormality of the endocrine system Diabetes mellitus Hyperglycemia Postprandial hyperglycemia
Primary Outcomes
Measure: Change in Hemoglobin A1c Time: Baseline and six months
Secondary Outcomes
Measure: Change in fasting plasma glucose Time: Baseline and six months
Measure: Change in systolic blood pressure Time: Baseline and six months
Measure: Change in total-to-HDL-cholesterol ratio Time: Baseline and six months
Measure: Change in body weight Time: Baseline and six months
Other Outcomes
Measure: Change in insulin Time: Baseline and six months
Measure: Change in homeostasis model assessment of insulin resistance (HOMA-IR) Time: Baseline and six months
Measure: Change in diastolic blood pressure Time: Baseline and six months
Measure: Change in waist circumference Time: Baseline and six months
Description: Based on 10-year cardiovascular disease risk assessed by 2013 American College of Cardiology/American Heart Association Atherosclerotic Cardiovascular Disease Risk Score
Measure: Change in estimated cardiovascular disease risk Time: Baseline and six months
HPO Nodes
Primary Outcomes
Measure: Change in Hemoglobin A1c Time: Baseline and six monthsSecondary Outcomes
Measure: Change in fasting plasma glucose Time: Baseline and six monthsMeasure: Change in systolic blood pressure Time: Baseline and six months
Measure: Change in total-to-HDL-cholesterol ratio Time: Baseline and six months
Measure: Change in body weight Time: Baseline and six months
Other Outcomes
Measure: Change in insulin Time: Baseline and six monthsMeasure: Change in homeostasis model assessment of insulin resistance (HOMA-IR) Time: Baseline and six months
Measure: Change in diastolic blood pressure Time: Baseline and six months
Measure: Change in waist circumference Time: Baseline and six months
Description: Based on 10-year cardiovascular disease risk assessed by 2013 American College of Cardiology/American Heart Association Atherosclerotic Cardiovascular Disease Risk Score
Measure: Change in estimated cardiovascular disease risk Time: Baseline and six months